Fractionated-dose radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody (epratuzumab).: Interim results.

被引：0
|
作者：
Chatal, JF
Harousseau, JL
Truemper, LH
Meller, J
Pfreundschuh, M
Kirsch, CM
Naumann, R
Kropp, J
Wegener, WA
Ding, C
Horak, ID
Goldenberg, DM
机构：
[1] Inst Biol, INSERM, Res Unit 4, Nantes, France
[2] Ctr Hosp Univ, Serv Hematol, Nantes, France
[3] Univ Gottingen, D-3400 Gottingen, Germany
[4] Univ Saarland, Sch Med, Hamburg, Germany
[5] Univ Hosp Dresden, Dresden, Germany
[6] Immunomed Inc, Morris Plains, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1482
引用
收藏
页码：408A / 408A
页数：1
相关论文
共 50 条
  • [41] Conventional and hematopoietic stem-cell-supported radioimmunotherapy (RAIT) with humanized 90Y-LL2 (90Y-hLL2) anti-CD22 monoclonal antibody (MAb) in NHL patients who failed high-dose chemotherapy (HDC).
    Juweid, M
    Matthies, A
    Alavi, A
    Shuster, S
    Dawns, L
    Luger, S
    Saleh, S
    Hajjar, G
    Sharkey, RM
    Rubin, A
    Stadtmauer, E
    Goldenberg, DM
    BLOOD, 1999, 94 (10) : 174A - 174A
  • [42] Anti-CD45 monoclonal antibody (MAb) dose optimization for astatine-211 (211At) -radioimmunotherapy (RIT) of relapsed non-Hodgkin lymphoma (NHL) in a canine model
    Frost, Sofia
    Miller, Brian
    Back, Tom
    Santos, Erlinda
    Hamlin, Donald
    Press, Oliver
    Storb, Rainer
    Wilbur, D. Scott
    Sandmaier, Brenda
    Pagel, John
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [43] Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody (MAB) in relapsed non-Hodgkin's lymphoma (NHL):: Dosimetry and radioimmunotherapy (RIT).
    Scheidhauer, K
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Wolf, I
    Reidel, G
    Peschel, C
    Schwaiger, M
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 268P - 268P
  • [44] Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDEC-Y2B8 yttrium-90 anti-CD20 monoclonal antibody.
    Wiseman, GA
    Dunn, WL
    Witzig, TE
    White, CA
    Grillo-López, AJ
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 69P - 70P
  • [45] Comparison of tumor targeting with 111In-labeled humanized anti-CD22 (111In hLL2) monoclonal antibody (MAB) scanning and 18FDG-PET in patients with relapsed non-Hodgkin's lymphoma.
    Matthies, A
    Cortés-Blanco, A
    Juweid, M
    Pourdehnad, M
    Goldenberg, DM
    Alavi, AA
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 276P - 276P
  • [46] Radioimmunotherapy with iodine-131 anti-CD20 chimeric monoclonal antibody (rituximab) for relapsed or refractory indolent non-Hodgkin's lymphoma: Results of an Australian phase II trial
    Leahy, MF
    Seymour, JF
    Hicks, RJ
    Turner, JH
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 156
  • [47] A phase II study of fludarabine phosphate and mitoxantrone followed by anti-CD20 monoclonal antibody in the treatment of patients with newly diagnosed, advanced low-grade non-Hodgkin's lymphoma (LGNHL): Interim results.
    Gregory, SA
    Venugopal, P
    Adler, S
    O'Brien, TM
    Porter, CP
    Yunus, F
    Robin, EL
    BLOOD, 2003, 102 (11) : 412A - 412A
  • [48] Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study).
    Martinelli, G
    Laszlo, D
    Conconi, A
    Rabascio, C
    Ferreri, AJ
    Pruneri, G
    Crosta, C
    Ponzoni, M
    Pedrinis, E
    Agazzi, A
    Zucca, E
    BLOOD, 2003, 102 (11) : 410A - 410A
  • [49] Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
    GrilloLopez, AJ
    Chinn, P
    Morena, R
    Varns, C
    Parker, E
    Solinger, AM
    BLOOD, 1995, 86 (10) : 207 - 207
  • [50] Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma
    Erwin, WD
    Spies, SM
    Kelly, ME
    Rao, P
    Eckersberg-Rhodes, TE
    Nannapaneni, M
    Groch, MW
    NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (02) : 247 - 255
12345